Rubella Diagnostic Testing Market Report 2024

This Rubella Diagnostic Testing market report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.

The rubella diagnostic testing market size has grown strongly in recent years. It will grow from $1.22 billion in 2023 to $1.3 billion in 2024 at a compound annual growth rate (CAGR) of 6.5%. The growth during the historic period can be attributed to factors such as the increase in vaccination programs, a rise in the incidence of immunization-preventable outbreaks, government initiatives aimed at combating the rubella virus, and the expansion of diagnostic testing in non-traditional settings.

The rubella diagnostic testing market size is expected to see strong growth in the next few years. It will grow to $1.68 billion in 2028 at a compound annual growth rate (CAGR) of 6.6%. The anticipated growth in the forecast period can be attributed to several factors, including increasing healthcare expenditures, a growing emphasis on preventive healthcare, rising awareness of vaccine-preventable diseases, expanded public health campaigns, and the growth of telemedicine and remote diagnostics. Key trends expected during this period include advancements in diagnostic technologies, the integration of technology within healthcare systems, the development of point-of-care testing solutions, the introduction of new diagnostic methods, and improvements in molecular diagnostics.

The increasing incidence of viral infections is anticipated to drive the growth of the rubella diagnostic testing market in the future. Viral infections are illnesses caused by viruses, which are tiny infectious agents that can only replicate within the living cells of a host organism. The rise in viral infections can be attributed to heightened global travel, which allows for the rapid spread of viruses across borders, as well as climate change, which modifies vector habitats and expands the distribution of disease-carrying organisms. Rubella diagnostic testing is crucial for early identification and management of rubella infections, helping to prevent complications, especially in pregnant women, and facilitating outbreak control to minimize virus transmission. For instance, in December 2023, the National Health Service, a UK government department, reported an average of 234 daily hospital admissions for flu, representing a 53% increase from the previous week. Additionally, hospital cases of norovirus rose by 15%, averaging 406 daily, which is a 28% increase compared to the same week last year. Consequently, the increasing cases of viral infections are propelling the growth of the rubella diagnostic testing market.

Key companies in the rubella diagnostic testing market are concentrating on developing innovative solutions, such as rubella virus vaccines, to improve diagnostic accuracy and enhance preventive measures. The rubella virus vaccine provides immunity against rubella and is often included in the MMR or MMRV combination vaccines to prevent the disease and its complications. For example, in March 2023, Merck & Co., Inc., a U.S.-based pharmaceutical company, received FDA approval for the intramuscular (IM) administration of its M-M-R II vaccine, which is essential for protecting against rubella, as well as measles and mumps. This approval enables healthcare providers to administer the rubella vaccine via the IM route, aligning it with other routinely recommended pediatric vaccines. Vaccination against rubella is critical for preventing outbreaks and safeguarding against the severe complications that the virus can inflict, particularly in pregnant women.

In September 2024, Leinco Technologies Inc., a U.S.-based developer of high-purity antibodies, acquired QED Biosciences for an undisclosed sum. This acquisition aims to expand Leinco Technologies' antibody product portfolio and development services, enhancing its capabilities in life sciences and in vitro diagnostics while supporting its growth strategy and commitment to innovation and quality for researchers worldwide. QED Biosciences specializes in developing novel monoclonal and polyclonal antibody products and offers rubella diagnostic testing services.

Major companies operating in the rubella diagnostic testing market are Cardinal Health Inc., Siemens Healthineers AG, Thermo Fisher Scientific Inc., Abbott Laboratories, F. Hoffmann-La Roche Ltd, bioMérieux S.A., Bio-Rad Laboratories Inc., Ortho-Clinical Diagnostics Inc., DiaSorin S.p.A., Meridian Bioscience Inc., Fortress Diagnostics Ltd., Mylab Discovery Solutions Pvt. Ltd., MP Biomedicals LLC, CTK Biotech Inc., ZEUS Scientific Inc., Creative Diagnostics, Arlington Scientific Inc., AccuBioTech Co. Ltd., Intec Products Inc., Vitrosens Biotechnology Ltd., Sprint Diagnostics Pvt. Ltd., InDevR Inc., Atlas Medical GmbH.

North America was the largest region in the rubella diagnostic testing market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the rubella diagnostic testing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the rubella diagnostic testing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Rubella diagnostic testing involves methods used to detect the presence of the rubella virus or antibodies in a patient's blood, confirming whether they have been infected with rubella or possess immunity against it. These tests enable healthcare providers to accurately diagnose rubella and manage its implications, particularly for vulnerable populations.

The primary types of diagnostic techniques used in rubella testing include latex agglutination, liver function tests, enzyme immunoassay (EIA), radioimmunoassay (RIA), fluorescent immunoassay (FIA), and others. Latex agglutination is a diagnostic approach where small latex beads coated with rubella-specific antigens or antibodies are mixed with a patient’s sample. This technique can be applied across various age groups, including neonates, teenagers, and adults, serving a wide range of end users such as hospitals, clinics, cancer diagnostic centers, and ambulatory surgical centers.

The rubella diagnostic testing market research report is one of a series of new reports that provides rubella diagnostic testing market statistics, including rubella diagnostic testing industry global market size, regional shares, competitors with a rubella diagnostic testing market share, detailed rubella diagnostic testing market segments, market trends and opportunities, and any further data you may need to thrive in the rubella diagnostic testing industry. This rubella diagnostic testing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The rubella diagnostic testing market consists of revenues earned by entities by providing services such as serological testing services, serologic tests, molecular diagnostic services, and rapid diagnostic testing services. The market value includes the value of related goods sold by the service provider or included within the service offering. The rubella diagnostic testing market also includes sales of serological assays, IgM antibodies, rapid diagnostic tests (RDTs), and polymerase chain reaction (PCR) tests. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.